Topic: Which in-process bioanalytics do we really need for cell-based therapy manufacture?

At our recent webinar we explored the shifting paradigm of quality in cell-based therapy manufacturing, with a particular focus on the core concept of embedding quality control in the process:

  • What does ‘quality’ mean in cell therapy, fundamentally?
  • Case studies on evolving autologous cell therapy QC approaches
  • How is in-process monitoring being embedded at the cutting edge today?

webinar 500x271


  • Dr Stephen Ward, Chief Operating Officer, Cell and Gene Therapy Catapult (moderator)
  • Dr Damian Marshall, Head of Analytical Development, Cell and Gene Therapy Catapult
  • Dr Sarah Snykers, QC Manager, Celyad
  • Dr John Elliott, Cell Systems Science Group, NIST

Click HERE to view the webinar on demand.